RxDoctor Payments Data

Michael Lauto, DO

Internal Medicine · Patchogue, NYNPI 1447339270

Payments from drug & device makers

$611in general payments, 2019–2025

Across 22 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$272
  • Novartis$183
  • Boehringer Ingelheim$47
  • AbbVie$33
  • Pfizer$23
  • Amgen$20
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$611 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$167,986
Medicare patients
79
Services billed
1,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol20$15,734
JanuviaSitagliptin Phosphate23$6,621
TradjentaLinagliptin11$5,684
SynthroidLevothyroxine Sodium12$1,489
Donepezil Hcl18$1,145
Rosuvastatin Calcium60$952
Metoprolol Succinate56$811
Atorvastatin Calcium71$672
Metformin Hcl ErMetformin Hcl36$604
Levothyroxine Sodium35$582
Lisinopril48$468
Memantine Hcl16$445
Famotidine28$357
Escitalopram Oxalate14$338
Ramipril24$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$272$15,73420 claims
Boehringer IngelheimTradjenta$47$5,68411 claims
AbbVieSynthroid$33$1,48912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Patchogue

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →